Stevanato Group S P A Stock Price, News & Analysis

Stevanato Group (NYSE: STVN) has secured €200 million in financing through agreements with multiple banks to support its capital expenditure projects. The funding breakdown includes €100 million from BNL BNP Paribas, €50 million from CDP, and €50 million from Banco BPM.

The financing will support expansion projects at the company's facilities in Cisterna di Latina (Italy) and Fishers (Indiana, U.S.). The funds will be used to enhance pre-filled syringe production, set up ready-to-use (RTU) cartridge capacity, and complete device manufacturing construction, supporting the company's growing biologics programs.

Stevanato Group (NYSE: STVN), a leading provider of drug containment, drug delivery, and diagnostic solutions, has scheduled its second quarter 2025 financial results announcement for August 5, 2025, at 6:30 a.m. ET.

The company will host a conference call and webcast at 8:30 a.m. ET on the same day. Management will reference a slide presentation available on the company's Investor Relations website. Participants can pre-register for immediate access or join through various dial-in numbers provided for Italy, United Kingdom, and United States.

Stevanato Group (NYSE: STVN), a leading provider of drug containment, delivery, and diagnostic solutions, has announced its participation in three major investor conferences in May and June 2025:

• Bank of America Securities Healthcare Conference in Las Vegas - May 14, 2025, at 5:00 p.m. PT
• William Blair Growth Stock Conference in Chicago - June 4, 2025, at 1:20 p.m. CT
• Jefferies Global Healthcare Conference in New York City - June 5, 2025, at 10:30 a.m. ET

Live webcasts will be available on the company's website under the "Investors" section, with replays accessible for approximately 90 days after each event.

Stevanato Group (NYSE: STVN) reported strong Q1 2025 financial results with revenue increasing 9% to €256.6 million. The growth was primarily driven by an 11% increase in the Biopharmaceutical and Diagnostic Solutions (BDS) Segment, while the Engineering Segment saw a 4% decline. High-value solutions represented 43% of total revenue, reaching €110.3 million. The company's gross profit margin improved by 80 basis points to 27.2%, and adjusted EBITDA margin increased 100 basis points to 22.4%. For fiscal 2025, Stevanato maintains its revenue guidance of €1,160-1,190 million but updated its adjusted EBITDA guidance to €288.5-301.8 million and adjusted EPS to €0.50-0.54 to reflect tariff impacts. The company generated strong free cash flow of €29.7 million in Q1 2025, with cash and cash equivalents of €90.7 million and net debt of €300.2 million at quarter-end.

Stevanato Group (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions, has scheduled its first quarter 2025 financial results announcement for Thursday, May 8, 2025, at 6:30 a.m. ET.

The company will host a conference call and webcast at 8:30 a.m. ET on the same day, featuring a management presentation with accompanying slides. These materials will be available on the company's Investor Relations website under the 'Financial Results' section.

Participants can access the call through pre-registration, direct dial-in numbers available for Italy, United Kingdom, and United States, or via a live webcast. A replay of the webcast will be archived for three months on the company's website.

Stevanato Group (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions for pharmaceutical, biotechnology, and life sciences industries, has announced its participation in the KeyBanc Capital Markets Healthcare Forum.

The event is scheduled for March 18-19, 2025, with the company's presentation set for Tuesday, March 18, at 3:00 p.m. ET. Investors and interested parties can access the live webcast through the 'Investors' section of Stevanato's website at www.stevanatogroup.com. The presentation recording will remain available for approximately 90 days following the event.

Stevanato Group (NYSE: STVN) reported record revenue of €1,104 million for fiscal year 2024, marking a 2% increase from the previous year. The company's fourth quarter revenue grew 3% to €330.6 million, with high-value solutions representing 40% of total revenue.

Key financial metrics for FY2024 include:

• Adjusted EBITDA margin of 23.5%
• Diluted EPS of €0.43 and adjusted diluted EPS of €0.48
• High-value solutions revenue increased 15% to €422.3 million
• Biopharmaceutical and Diagnostic Solutions segment grew 6% to €933.7 million
• Engineering segment declined 17% to €170.3 million

For 2025, the company projects revenue between €1,160-1,190 million, adjusted EBITDA of €293.0-306.3 million, and adjusted diluted EPS of €0.51-0.55.

Stevanato Group (NYSE: STVN), a leading provider of drug containment, drug delivery, and diagnostic solutions, has scheduled its Fourth Quarter and Fiscal Year 2024 financial results announcement for March 6, 2025, at 6:30 a.m. ET.

The company will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss the results. Management will reference a slide presentation available on the company's Investor Relations website. Participants can pre-register for immediate access to the call, while a live webcast will also be available. The webcast recording will be archived for three months on the company's Investor Relations section.

Stevanato Group (NYSE: STVN), a global leader in drug containment and delivery solutions for pharmaceutical, biotechnology, and life sciences industries, has announced its participation in the CJS Securities 25th Annual "New Ideas for the New Year" Investor Conference. The presentation is scheduled for Tuesday, January 14, 2025, at 8:00 a.m. ET.

The company will provide a live webcast of the event through their website at www.stevanatogroup.com in the "Investors" section. Interested parties who cannot attend the live presentation can access a replay of the webcast, which will remain available for approximately 90 days following the event.